FOI 2024-035

I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.

Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.

1.      How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?

A)      Biliary Tract Cancer

B)      Non-Small Cell Lung Cancer

2.      How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).

3.      How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?

C)      Biliary Tract Cancer

D)      Non-Small Cell Lung Cancer

4.      How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?

E)      Biliary Tract Cancer

F)      Non-Small Cell Lung Cancer